Heart failure clinical trials

Explore recruiting heart failure clinical trials.

Recruiting heart failure studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Heart failure trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Corticotrophin Releasing Factor 2 Agonist For the Treatment of Worsening Heart Failure (WHF) – The CRAFT-WHF Study

Czechia, Spain, Romania, Hungary, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Withdrawal of Pharmacological Treatment in Patients Responding to Cardiac Resynchronization Therapy: (REMOVE)

Spain

Therapeutic use (Phase IV) EU CTIS Study details

EASi-HF Reduced – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40%

Hungary, Slovakia, Czechia, Belgium, Italy, Bulgaria +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients Who Have Been Stabilized During Hospitalization for Acute Heart Failure

Poland, Hungary, Czechia

Phase III and phase IV (Integrated) EU CTIS Study details

Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) Metformin in Patients with Chronic Heart Failure and Diabetes or Insulin Resistance - Metformin Heart Failure Trial (Met-HeFT) A randomized, 2 x 2 factorial designed, double-blind, placebo controlled study (DANHEART).

Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Effects of Digoxin in Modern Heart Failure Treatment

Portugal

Therapeutic use (Phase IV) EU CTIS Study details

Heart failure trials by city

Heart failure in Toronto Heart failure in Vancouver Heart failure in Montreal Heart failure in Calgary Heart failure in Edmonton Heart failure in Ottawa Heart failure in Winnipeg Heart failure in Quebec City Heart failure in Hamilton Heart failure in Kitchener Heart failure in London Heart failure in Halifax Heart failure in New York Heart failure in Los Angeles Heart failure in Chicago Heart failure in Houston

Other conditions

Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease IgA nephropathy Polycystic kidney disease Migraine